Recap: Biomarin Pharmaceutical Q4 Earnings

Biomarin Pharmaceutical BMRN reported its Q4 earnings results on Thursday, February 22, 2024 at 04:05 PM.

Here's what investors need to know about the announcement.

Earnings

Biomarin Pharmaceutical beat estimated earnings by 113.04%, reporting an EPS of $0.49 versus an estimate of $0.23.

Revenue was up $108.67 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.24 which was followed by a 5.17% drop in the share price the next day.

Here's a look at Biomarin Pharmaceutical's past performance:

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

Biomarin Pharmaceutical management provided guidance for FY 2024, expecting earnings between $2.6 and $2.8 per share.

To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.